NCM
ATXI

Nantahala Capital Management’s Avenue Therapeutics, Inc. Common Stock ATXI Stock Holding History

Nantahala Capital Management’s Portfolio ATXI Stock Details ATXI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-1,292
Closed -$1.32M – 139
2021
Q4 		$1.32M Buy
1,292
+1,265
+4,685% +$1.83M 0.05% 116
2021
Q3 		$45K Hold
27
– – ﹤0.01% 130
2021
Q2 		$76K Hold
27
– – ﹤0.01% 121
2021
Q1 		$183K Hold
27
– – 0.01% 116
2020
Q4 		$180K Buy
+27
New +$142K 0.01% 113

Other funds holding ATXI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BRWA
B. Riley Wealth Advisors Boca Raton, Florida $1.87B AUM 37.01% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Nantahala Capital Management's ATXI Position: Q1 2022 in Review

Nantahala Capital Management sold out of Avenue Therapeutics, Inc. Common Stock (ATXI) in Q1 2022, closing a stake of 1,292 shares — an estimated $1.32M sold.

Nantahala Capital Management first reported a position in ATXI in Q4 2020 and held it in 5 quarters. The position peaked at $1.32M in Q4 2021. 14 funds tracked by Wall St. Rank hold ATXI as of Q1 2022.

  • Nantahala Capital Management reported no remaining Avenue Therapeutics, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
  • Nantahala Capital Management sold 1,292 Avenue Therapeutics, Inc. Common Stock shares in Q1 2022, an estimated $1.32M.
  • Nantahala Capital Management first reported a position in Avenue Therapeutics, Inc. Common Stock in Q4 2020 and held it in 5 quarters.
  • Nantahala Capital Management's Avenue Therapeutics, Inc. Common Stock position peaked at $1.32M in Q4 2021.
  • 14 funds tracked by Wall St. Rank held Avenue Therapeutics, Inc. Common Stock as of Q1 2022.

Based on Nantahala Capital Management's 13F filing for Q1 2022, filed 13 May 2022.